Danaher enters gene therapy consortium

By The Science Advisory Board staff writers

May 16, 2022 -- Danaher has joined the Bespoke Gene Therapy Consortium (BGTC), which generates gene therapy resources aimed at rare disorders.

Besides Danaher's life science companies such as Pall, Aldevron, and Cytiva, other consortium members include the U.S. Food and Drug Administration, the National Institutes of Health, 12 pharmaceutical and biotech companies, and nine nonprofits. The Foundation for the National Institutes of Health manages the consortium as part of the Accelerating Medicines Partnership program.

The BGTC was formed in October 2021 in response to shortcomings in the current drug development model that makes it difficult for companies to recover the costs required to develop gene therapies to treat rare and ultra-rare diseases, Danaher said.

Cytiva, Pall to invest $1.5B in biomanufacturing over next 2 years
Cytiva and Pall, both Danaher companies, will make major investments in manufacturing capacity and services at 13 sites around the globe supporting life...

Copyright © 2022 scienceboard.net

Microscopy and Microanalysis Meeting
July 31 - August 4
Portland, Oregon United States
Glasgow International Health Festival
August 24-27
Glasgow, Glasgow City United Kingdom
Pharma Competitive Intelligence Conference and Exhibition
September 21-22
Newark, New Jersey United States
BioProcess International (BPI) Conference
September 27-30
Boston, Massachusetts United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter